Skip to main content
. 2022 Jun 21;13(9):2781–2797. doi: 10.7150/jca.73690

Figure 5.

Figure 5

ARHGAP24 is a direct target of miR-21 in pancreatic ductal adenocarcinoma. (A and B) RT-qPCR and western blotting were used to analyze cells transfected with the miR-21 inhibitor, miR-21 mimic or the corresponding controls. (C) Immunohistochemistry was used to assess xenograft tumors following transfection with SP-NC or SP-miR-21 MIA PaCa-2 cells (scale bar, 100 µm; image magnification, x200). (D) Predicted interaction between miR-21 and its putative binding sites in the 3'UTR of ARHGAP24. (E) Luciferase activity of ARHGAP24 wild-type and mutated-type transfected with the miR-21 mimic or miR-21 inhibitor. (F) Expression level of ARHGAP24 mRNA after transfected with si-ARHGAP24 or ARHGAP24 plasmid was evaluated by qRT-PCR. (G) Expression levels of ARHGAP24, proliferation markers, cell cycle-related proteins and apoptosis-related proteins in PANC-1 and MIA PaCa-2 cells following transfection with si-ARHGAP24 and the ARHGAP24 plasmid, or the control. All experiments were performed in triplicate. Data are presented as the mean ± SD. *P<0.05, **P<0.01 and ***P<0.001.